Orodispersible Tablets of Epalrestat for Immediate Release Studies

Alvi, Z; Nazir, I; Javed, ZA; Abbas, G; Hanif, M; Shehzad, MA

Hanif, M (reprint author), Bahauddin Zakariya Univ, Fac Pharm, Multan, Pakistan.

LATIN AMERICAN JOURNAL OF PHARMACY, 2019; 38 (4): 813

Abstract

Compression of orodispersible tablets remained a challenge for the pharmaceutical scientists due to different nature of excipients. In the present study, effect of powder, granules and combination of powder and granules were evaluated. Three different types of materials were finally optimized by using Box-Behnken design by taking avicel, magnesium stearate and mannitol as factors and micromeritic properties of powder, granules and powder and granules combination like angle of repose, bulk density, tapped density, Carr's index and Hausner's ratio as responses. Compressed tablets were further evaluated by physicochemical studies like hardness, friability, weight variation, revised in vitro disintegration, wetting time, water absorption ratio, and percentage release studies by using phosphate buffer pH 7.4. All the micromeritic properties and physicochemical test of the compressed formulations were within the acceptable limit. Compatibility of excipients and drug were further analyzed by FTIR and characteristics peaks were obtained at 3743, 3673, 3649, 1741, 1680, and 1472 cm(-1) corresponds to the peaks of mannitol, magnesium stearate, avicel, and epalrestat, respectively, indicating no chemical interactions between drug, polymer, and excipients. Significant amount of more than 85% release of Epalrestat was observed from compressed formulation. In vivo studies for the treatment of diabetic neuropathy, nephropathy and retinopathy can be studied due to potential effects of epalrestat as already reported in previous inquiries.

Download PDF


Full Text Link